Pdk1 binding molecules and uses thereof
OwnerScott Kendall Dessain, Baron Christopher Heimbachinventors
Life of this patent
Estimating the term…
Abstract
The present invention is based, at least in part, on the discovery that PDK1 is associated with the outer plasma membrane of the cell. Accordingly, the present invention encompasses 3-phosphoinositide-dependent protein kinase-1 (PDK1) binding molecules, such as an antibody. The binding molecules of the invention are useful for detecting PDK1 and for inhibiting PDK1 activity, e.g., in a human subject having a disorder in which PDK1 activity is detrimental, such as a cancer.
Claims33
A binding molecule which binds to extracellular 3-phosphoinositide-dependent protein kinase-1 (PDK1).
A method of treating a cancer in a subject in need thereof comprising:
- (a) obtaining a sample from a subject having cancer;
- (b) testing the sample for expression of extracellular 3-phosphoinositide-dependent protein kinase-1(PDK1);
- and
- (c) administering to the subject a therapeutically effective amount of a PDK1 inhibitor.
A nucleic acid encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular binding domain capable of binding to extracellular PDK1, a transmembrane domain, and an intracellular signaling domain.
An isolated anti-PDK1 human antibody, or antigen binding portion thereof, produced by hybridoma cell line 2B9 (ATCC Accession No. ______).
The hybridoma cell line 2B9 deposited under ATCC Accession No. ______.
Dependencies are inferred from the claim text.